Method for gene repair of hematopoietic stem cells of alpha-deletion thalassemia
Through CRISPR/Cas9 gene editing technology and E. coli T7 RNA polymerase transcription method, Cas9 mRNA and gRNA were co-transfected into α-deleted thalassemia hematopoietic stem cells, achieving dual-gene site-directed insertion, solving the safety and low efficiency of gene editing vectors The problem of successfully repairing the α-globin gene provides the possibility of lifelong treatment.
Patent Information
- Application Number
- CN202410948486.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-15
AI Technical Summary
Prior art In the treatment of alpha-deletion thalassemia, gene editing vectors and methods have problems with inefficiency, especially in avoiding the risk of carcinogenicity and improving the efficiency of homologous recombination.
Using CRISPR/Cas9 gene editing technology, the extracellular transcription of E. co-transfection of Cas9 mRNA, two Donor DNA and four gRNAs to -SEA/-α3.7 gene-deletion thalassemia hematopoietic stem cells were obtained using E. coli T7 RNA polymerase High-quality gRNA and Cas9 mRNA achieve dual-gene site-directed insertion, overcome the risk of carcinogenicity of lentiviral vectors and improve gene editing efficiency.
The hematopoietic stem cells with gene repair were successfully sorted and verified, which normalized the transcription level of α-globin protein mRNA, provided lifelong treatment hope, avoided the risk of carcinogenicity of lentiviral vectors, and improved the efficiency and safety of gene editing. sex.
Smart Images

Figure CN118956956A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of stem cells, and in particular relates to a method for gene repair of hematopoietic stem cells in α-deficient thalassemia. Background Art
[0002] Thalassemia is one of the most common single gene genetic diseases, with about 80 million carriers worldwide, mainly distributed in the Mediterranean region, followed by the Middle East, India, Pakistan, Southeast Asia, North Africa and some areas in southern China. The high-incidence areas in my country are mainly distributed in provinces and regions south of the Yangtze River, among which Guangxi, Guangdong and Hainan have the highest incidence rates. α-thalassemia is a hereditary hemolytic anemia that poses a serious threat to human health. It is caused by point mutations or deletions in the α-globin gene and its regulatory sequences, resulting in a reduction or complete cessation of α-globin peptide chain synthesis.
[0003] Blood transfusion therapy for intermediate and severe thalassemia can relieve anemia symptoms, but it will aggravate the deposition of iron ions, eventually leading to organ failure and death. At present, the only possible means to cure thalassemia is bone marrow transplantation. However, allogeneic bone marrow transplantation faces two difficulties: immune rejection and graft-versus-host disease, so it is necessary to find a donor with matching major histocompatibility antigens to avoid the above-mentioned rejection reaction. In the absence of donors, gene modification and re-infusion of autologous hematopoietic stem cells has become a hope for the treatment of thalassemia. Compensation of normal α-globin through gene therapy is the most direct way to treat α-thalassemia. Hematopoietic stem cells have the ability to rebuild the omnipotence and self-renewal of an individual's hematopoietic system. In theory, the normal α-globin gene is introduced into hematopoietic stem cells to repair abnormal chromosomal DNA sequences and transfused back into the body so that it can be properly expressed, and the patient will receive lifelong treatment. This is the gene therapy for α-thalassemia. However, hematopoietic stem cell gene repair has always faced challenges. Solving these difficulties requires finding safe and effective gene editing vectors and gene editing methods. Summary of the invention
[0004] The purpose of the present invention is to provide a method for gene repair of hematopoietic stem cells for α-deficient thalassemia, belonging to the technical field of stem cells.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] First, the present invention provides a method for gene repair of hematopoietic stem cells with α-deficient thalassemia, wherein the method for gene repair of hematopoietic stem cells is to co-transfect a Cas9 mRNA, two Donor DNAs and four gRNAs into -SEA / -α3.7 gene-deficient thalassemia hematopoietic stem cells, and sort the hematopoietic stem cells into which the SEA and α3.7Donor DNA double genes are site-specifically inserted into the gene-deficient region.
[0007] Furthermore, the method for repairing the hematopoietic stem cell gene is:
[0008] (1) Bone marrow cell suspension of -SEA / -α3.7 thalassemia patients was used to separate leukocytes using Ficoll solution, and CD34+ cells were enriched using CD34 magnetic beads;
[0009] (2) the isolated CD34+ hematopoietic stem cells are expanded using hematopoietic stem cell serum-free medium;
[0010] (3) extracellular transcription by Escherichia coli T7 RNA polymerase to obtain gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA;
[0011] (4) SEA Donor DNA, α3.7 Donor DNA, gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA were co-transfected into cultured hematopoietic stem cells;
[0012] (5) 24 hours after transfection, single cells with green fluorescence were sorted by flow cytometry into 96-well plates and cultured for 21 days;
[0013] (6) Extracting genomic DNA from cultured hematopoietic stem cells after sorting, detecting the integration of SEA Donor DNA and α3.7 Donor DNA in the genome by PCR, and confirming the acquisition of gene-repaired hematopoietic stem cells by gene sequencing.
[0014] Furthermore, the nucleotide sequence of the gRNA transcription template for -SEA gene repair is SEQ ID NO.1, SEQ ID NO.2, and the nucleotide sequence of SEA Donor DNA is SEQ ID NO.5.
[0015] Furthermore, the nucleotide sequences of the gRNA transcription template for -α3.7 gene repair are SEQ ID NO.6 and SEQID NO.7, and the nucleotide sequence of the SEA Donor DNA is SEQ ID NO.10.
[0016] Furthermore, the E. coli T7 RNA polymerase extracellular transcription method is:
[0017] (1) Escherichia coli BL21 (DE3) strain was inoculated into LB medium at a ratio of 1% and cultured at 37°C with shaking at 220 rpm / min for 3 h;
[0018] (2) IPTG at a final concentration of 1 mM induces the lacUV5 promoter to direct the transcription of the T7 RNA polymerase gene to produce T7 RNA polymerase;
[0019] (3) IPTG induced transcription for 3 hours, and the cells were collected and resuspended in 1 / 10 volume of 1 mM Tris-HCl (pH 7.5) of the original LB medium. The cells were broken by ultrasonic disruptor, centrifuged for 5 minutes, and the supernatant enzyme solution was collected;
[0020] (4) using a universal nuclease to degrade the DNA and RNA in the enzyme solution, then adding a universal nuclease monoclonal antibody to neutralize the universal nuclease activity, and centrifuging to collect the supernatant, which is the T7 RNA polymerase mixture used for transcription;
[0021] (5) 50ul of T7 RNA polymerase mixture, 5μL of 10mM ATP, CTP, GTP, and UTP mixture, 1μg of the plasmid to be transcribed, and ultrapure water to make up the reaction system to 100μL. Mix well and transcribe at 37°C for 60min.
[0022] (6) After transcription, add 5 μL of deoxyribonuclease (DNase) to degrade the DNA in the system;
[0023] (7) RNA purification to obtain transcribed gRNA or mRNA.
[0024] Furthermore, the density of the hematopoietic stem cells during transfection was 1×10 6 cells / mL, and 2.5 μg of SEA Donor DNA and α3.7Donor DNA, and 1 μg of gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA were co-transfected in 100 μL of cells.
[0025] Second, the present invention provides an Escherichia coli T7 RNA polymerase extracellular transcription method, the transcription method is:
[0026] (1) Escherichia coli BL21 (DE3) strain was inoculated into LB medium at a ratio of 1% and cultured at 37°C with shaking at 220 rpm / min for 3 h;
[0027] (2) IPTG at a final concentration of 1 mM induces the lacUV5 promoter to direct the transcription of the T7 RNA polymerase gene to produce T7 RNA polymerase;
[0028] (3) IPTG induced transcription for 3 hours, and the cells were collected and resuspended in 1 / 10 volume of 1 mM Tris-HCl (pH 7.5) of the original LB medium. The cells were broken by ultrasonic disruptor, centrifuged for 5 minutes, and the supernatant enzyme solution was collected;
[0029] (4) using a universal nuclease to degrade the DNA and RNA in the enzyme solution, then adding a universal nuclease monoclonal antibody to neutralize the universal nuclease activity, and centrifuging to collect the supernatant, which is the T7 RNA polymerase mixture used for transcription;
[0030] (5) 50ul of T7 RNA polymerase mixture, 5μL of 10mM ATP, CTP, GTP, and UTP mixture, 1μg of template DNA to be transcribed, and ultrapure water to make up the reaction system to 100μL. Mix well and transcribe at 37℃ for 60min.
[0031] (6) After transcription, add 5 μL of deoxyribonuclease (DNase) to degrade the DNA in the system;
[0032] (7) RNA purification to obtain transcribed gRNA or mRNA.
[0033] The beneficial effect of the present invention is that, by culturing hematopoietic stem cells of patients with α-deficient thalassemia in vitro and applying CRISPR / Cas9 gene editing technology, one Cas9 mRNA, two Donor DNAs and four gRNAs are co-transfected into -SEA / -α3.7 gene-deficient thalassemia hematopoietic stem cells, and sorted into hematopoietic stem cells with double gene site-specific insertion into gene-deficient regions. The double gRNA used in the present invention guides the Cas9 protein to cut the target gene upstream and downstream of the deleted gene, and the homologous recombination efficiency of Donor DNA is high. The transfection amount of Cas9mRNA is controlled so that the Cas9 protein is transiently expressed in the cell to produce an incision on the edited cell genome for homologous recombination of Donor DNA. Thereafter, Cas9 mRNA is rapidly degraded to prevent secondary cutting of the Donor DNA that has completed homologous recombination, so that the repair of the deleted gene by Donor DNA will not be destroyed. The Cas9 mRNA transfection method overcomes the carcinogenic and pathogenic risks of gene editing with viral vectors such as lentivirus, which are currently widely used. In addition, the present invention uses the lysate of BL21 Escherichia coli induced by high efficiency to obtain T7 RNA polymerase, and drives the gene transcription under the control of T7 promoter outside the cell to obtain high-quality gRNA and Cas9mRNA, thereby realizing one-time transfection of multiple gRNAs, realizing one-time repair of multiple target genes, and improving gene editing efficiency. This RNA transcription method has the advantages of simple operation and low cost. The present invention successfully sorts gene-repaired hematopoietic stem cells by flow cytometer sorting, PCR detection and gene sequencing. Gene-repaired hematopoietic stem cells are differentiated into erythroid cells by in vitro differentiation induction culture. Compared with normal cells, the transcription level of α-globin protein mRNA after differentiation induction of hematopoietic stem cells repaired by -αSEA and -α3.7 gene deletion fragments reached normal levels. It is very promising to obtain lifelong treatment when the gene-repaired hematopoietic stem cells are infused back to the patient. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 :gRNA transcription template design map.
[0035] Figure 2:pX458-T7Cas9 plasmid map.
[0036] Figure 3 :Detection of α-globin protein transcription level before and after gene repair. DETAILED DESCRIPTION
[0037] Example 1: Isolation and culture of hematopoietic stem cells
[0038] (1) Add 7.5 ml of Ficoll solution with a specific gravity of 1.017 to a 15 ml separation tube, slowly transfer an equal amount of bone marrow cell suspension, centrifuge at 2000 r / min at 4°C for 20 min after overall balance, aspirate the white blood cell layer, wash with RPMI1640 medium, and centrifuge at 2000 r / min at 4°C for 10 min. Take the white blood cell layer and add RPMI1640 medium to 10 ml to prepare a hematopoietic stem cell suspension sample.
[0039] (2) The isolated hematopoietic stem cell suspension sample was incubated with FcR Blocking Reagent and CD34 MicroBeads μLtraPure at 2-8°C for 30 minutes. The cells were washed and centrifuged to remove excess unlabeled magnetic beads, and the cells were resuspended to an appropriate volume.
[0040] (3) According to the total cell count and CD34+ cells, select the appropriate MACS column and MACS separator. After incubation with CD34 MicroBeads, the cell mixture passes through the column, and the CD34+ cells are adsorbed by the magnetic beads in the column; while the non-CD34+ cells flow out of the column. After several washes, the flow-through can obtain CD34+ cells with higher purity. Through magnetic bead sorting, hematopoietic stem cells are enriched because they contain CD34+ cells.
[0041] (4) Take freshly isolated CD34+ hematopoietic stem cells and adjust the cell density to 1×10 5 50μg / L recombinant stem cell growth factor (rhSCF), 10μg / L rhGM-CSF, 10μg / L recombinant interleukin 1 (rhIL-1), and 10μg / L recombinant interleukin 6 (rhIL-6) were added to the serum-free medium of StemSpanSFEMII hematopoietic stem cells. The cells were placed in a CO2 incubator with 5% CO2 and 37°C saturated humidity. Half of the medium was replaced every 7 days. After 3 weeks, the bottom of the culture well was covered with a monolayer of cells, and the cells were digested and passaged with 1% trypsin.
[0042] Example 2: Design of gRNA and gene repair Donor fragment for αSEA-deficient thalassemia
[0043] (1) Based on the human chromosome 16 sequence NT_086364.3 and the α-globin gene SEA deletion sequence KX458114.1, a gRNA was designed upstream and downstream of SEA to guide the Cas9 enzyme to cut genomic DNA upstream and downstream of the SEA deletion region. The gRNA coding fragment structure was designed as follows Figure 1 As shown, Hammerhead ribozyme, gRNA, gRNA scaffold, HDV ribozyme and T7 terminator are sequentially connected to the T7 promoter. A gene synthesis company was commissioned to synthesize the gRNA1 coding fragment SEQ ID NO.1 and the gRNA2 coding fragment SEQ ID NO.2, which were cloned into the pUC57 plasmid, respectively, to obtain pUC57-gRNA1 and pUC57-gRNA2.
[0044] (2) 100 bp upstream of gRNA1 and 100 bp downstream of gRNA2 were selected as the insertion sequence homology arms, and the primer pair SEAf / SEAr was designed to amplify the SEA Donor sequence using the healthy human genome as a template. The Donor DNA fragment was amplified by PCR using the NEBNext Q5 Hot Start HiFiPCR Master Mix (New England Biolabs) high-fidelity enzyme system. The PCR reaction was a 50 μL system, the primer concentration was 0.5 μM, and 2 μL of normal human genomic DNA was used as a template. The PCR program was: 98°C pre-denaturation for 30 s; 98°C denaturation for 10 s, 55°C annealing for 20 s, and 72°C extension for 70 s; and finally 72°C extension for 5 min. The PCR product was subjected to 1.5% agarose gel electrophoresis, and the 1136 bp target band was cut out. The target fragment was recovered and purified using an agarose gel recovery kit as the gene repair insert fragment SEA Donor DNA. The SEA Donor sequence is SEQ ID NO.5.
[0045] Example 3: -α 3.7 Design of gRNA and gene repair Donor fragment for deletion-type thalassemia
[0046] (1) Based on the human chromosome 16 sequence NT_086364.3 and α-globin gene-α 3.7 Deletion sequence AF525460.1, in α 3.7 Design a gRNA upstream and downstream to guide the Cas9 enzyme in α 3.7The genomic DNA was cut upstream and downstream of the deletion region. Hammerhead ribozyme, gRNA, gRNA scaffold, HDV ribozyme and T7 terminator were connected to the T7 promoter in sequence. A gene synthesis company was commissioned to synthesize the gRNA3 encoding fragment SEQ ID NO.6 and the gRNA2 encoding fragment SEQ ID NO.7, which were cloned into the pUC57 plasmid, respectively, to obtain pUC57-gRNA3 and pUC57-gRNA4.
[0047] (2) Select 100 bp upstream of gRNA3 and 100 bp downstream of gRNA4 as the insertion sequence homology arms, and design primer pair α 3.7 f / α 3.7 r, amplification of α using the genome of a healthy person as a template 3.7 Donor sequence. The Donor DNA fragment was amplified by PCR using the NEBNext Q5 Hot Start HiFiPCR Master Mix (New England Biolabs) high-fidelity enzyme system. The PCR reaction was a 50 μL system with a primer concentration of 0.5 μM and 2 μL normal human genomic DNA as a template. The PCR program was: 98°C pre-denaturation for 30 s; 98°C denaturation for 10 s, 55°C annealing for 20 s, and 72°C extension for 115 s; and finally 72°C extension for 5 min. The PCR product was subjected to 1.5% agarose gel electrophoresis, and the 1910 bp target band was cut out. The target fragment was recovered and purified using an agarose gel recovery kit as the gene repair insert fragment α 3.7 Donor DNA, α 3.7 The Donor sequence is SEQ ID NO.10.
[0048] (3) Construction of pX458-T7Cas9 plasmid for in vitro transcription of Cas9 protein mRNA. T7 promoter drives Cas9 gene transcription. The pX458-T7Cas9 plasmid map is shown in Figure 2 .
[0049] Example 4: Preparation of gRNA and Cas9mRNA
[0050] (1) Escherichia coli BL21 (DE3) strain was inoculated into LB medium at a ratio of 1%, and cultured at 37℃ and 220 rpm / min for 3 hours. IPTG was added at a final concentration of 1 mM to induce the lacUV5 promoter to direct the transcription of the T7 RNA polymerase gene and produce T7 RNA polymerase. After adding IPTG, the culture was cultured at 37℃ and 220 rpm / min for 3 hours, and centrifuged at 12000 rpm / min for 5 minutes. The bacterial precipitate was washed three times with ultrapure water without RNAse, and the bacterial cells were resuspended with 1 / 10 volume of 1 mM Tris-HCl (pH 7.5) of the original LB medium, and the bacterial cells were broken by ultrasonic disruptor on ice, and centrifuged at 12000 rpm / min for 5 minutes, and the supernatant enzyme solution was collected. The supernatant enzyme solution was added with universal nuclease, mixed, and then allowed to stand at 37℃ for 60 minutes to degrade the DNA and RNA in the enzyme solution. Universal nuclease monoclonal antibody was added, mixed, and then allowed to stand at 37℃ for 60 minutes to neutralize the activity of universal nuclease. After treatment, centrifuge at 12000 rpm / min for 5 min, and collect the supernatant, which is the T7 RNA polymerase mixture used for transcription.
[0051] (2) Prepare the T7 RNA polymerase mixture transcription system by taking pUC57-gRNA1, pUC57-gRNA2, pUC57-gRNA3, pUC57-gRNA4 and pX458-T7Cas9 plasmids respectively.
[0052] (3) 50ul of T7 RNA polymerase mixture, 5μL of 10mM ATP, CTP, GTP, and UTP mixture, 1μg of the plasmid to be transcribed, and ultrapure water to make up the reaction system to 100μL. Mix well and let stand at 37℃ for 60min. Add 5μL of deoxyribonuclease (DNase) to the reaction solution, mix well and let stand at 37℃ for 60min. Use RNeasy mini kit to extract the transcribed RNA. Dissolve gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA in 20μL TE buffer and store in aliquots at -80℃.
[0053] Example 5: Gene repair of α-deficient thalassemia gene in bone marrow hematopoietic stem cells
[0054] (1) Bone marrow hematopoietic stem cells with the genotype of -SEA / -α3.7 intermedia were passaged 36 hours before transfection. When the cell confluence in the cell culture flask reached 80%, the cells were digested with 1% trypsin, 20 mL of StemSpan SFEMII hematopoietic stem cell serum-free medium was added, the cells were counted, centrifuged at 1000 rpm for 10 min, and the cells were resuspended in StemSpan SFEMII hematopoietic stem cell serum-free medium to adjust the cell density to 1×10 6 cells / mL.
[0055] (2) Pipette 100 μL of cells into a 1.5 mL EP tube, add 2.5 μg each of SEA Donor DNA and α3.7 Donor DNA, 1 μg each of gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA, mix well with a pipette tip, and then pipette 100 μL of the mixture into a 4 mm electroporation cup. Place the electroporation cup in an ECM 830 electroporator, set the electroporation parameters to 250 V, 6 msec, 625 V / cm, and perform one electric shock. Immediately after the electric shock, transfer the cells to a 6-well cell culture plate and place them in a CO2 incubator with 5% CO2 and saturated humidity at 37°C for 24 hours. Use a flow cytometer to sort single cells with green fluorescence into a 96-well plate. Replace half of the culture medium every 7 days, and after 21 days, the bottom of the culture well is covered with a monolayer of cells. The cells were digested with 1% trypsin, and the cell genomic DNA was extracted. The primer pair SEAf / SEAr was used for PCR amplification to detect whether the SEA Donor DNA was site-specifically inserted into the cell genome. The primer pair α3.7f / α3.7r was used for PCR amplification to detect whether the α3.7Donor DNA was site-specifically inserted into the cell genome.
[0056] (3) The results showed that the gene repair was successful. The cells with the correct SEA Donor DNA inserted could amplify the 1136bp band, and the cells with the correct α3.7Donor DNA inserted could amplify the 1910bp band. After a large number of screenings, a cell line was obtained that could amplify both the 1136bp band and the 1910bp band. DNA sequencing confirmed that the cell had the SEA Donor DNA and α3.7DonorDNA sequences correctly inserted, and both double-deleted genes were repaired.
[0057] Example 6: Verification of bone marrow hematopoietic stem cell function after repair
[0058] (1) The α-globin protein-SEA / -α3.7 double gene deletion was screened and the bone marrow hematopoietic stem cells were inserted and repaired, and StemSpan SFEMII serum-free medium was added with 50μg / L recombinant stem cell growth factor (rhSCF), 10μg / L recombinant interleukin 3 (rhIL-3), 0.5U / ml recombinant human erythropoietin (rhEPO), and 1× cholesterol lipid, and cultured in a CO2 incubator with 5% CO2 and saturated humidity at 37°C for 21 days. Then, StemSpan SFEMII serum-free medium was added with 50μg / L recombinant stem cell growth factor (rhSCF), 10μg / L recombinant interleukin 3 (rhIL-3), recombinant human erythropoietin (0.5U / ml), 1× cholesterol lipid, 50μg / mL iron ion saturated transferrin, and 3U / ml recombinant human erythropoietin (rhEPO), and cultured for another 21 days. Hematopoietic stem cells differentiate into red blood cells through in vitro differentiation induction culture.
[0059] (2) Total RNA of cells after differentiation induction was extracted using RNeasy mini kit, and qRT-PCR was performed using TaqMan probe primers targeting α-globin mature mRNA to detect the transcription level of α-globin gene. The primers and probes used are as follows:
[0060] αF:CCACCACCAAGACCTACTTC,
[0061] αR:TCGGCCACCTTCTTGCCGTG,
[0062] αPFAM-BHQ1:CACTTCGACCTGAGCCACGGCTCTG.
[0063] The results showed that compared with cells with normal α-globin protein gene, the α-globin protein mRNA transcription level of bone marrow hematopoietic stem cells with -SEA / -α3.7 gene deletion after hematopoietic stem cell differentiation induction was only 20.54% of that of normal cells. The α-globin protein mRNA transcription level of cells after gene repair was no different from that of normal cells and reached the normal level.
Claims
1. A method for gene repair of hematopoietic stem cells in α-deficient thalassemia, It is characterized in that The method for gene repair of hematopoietic stem cells is to co-transfect one Cas9 mRNA, two Donor DNAs and four gRNAs into -SEA / -α3.7 gene-deficient thalassemia hematopoietic stem cells, and sort the hematopoietic stem cells into which the SEA and α3.7 Donor DNA double genes are site-specifically inserted into the gene-deficient region.
2. The method according to claim 1, It is characterized in that The method for repairing the hematopoietic stem cell gene is: (1) Bone marrow cell suspension of -SEA / -α3.7 thalassemia patients was used to separate leukocytes using Ficoll solution, and CD34+ cells were enriched using CD34 magnetic beads; (2) the isolated CD34+ hematopoietic stem cells are expanded using hematopoietic stem cell serum-free medium; (3) extracellular transcription by Escherichia coli T7 RNA polymerase to obtain gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA; (4) SEA Donor DNA, α3.7 Donor DNA, gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA were co-transfected into cultured hematopoietic stem cells; (5) 24 hours after transfection, single cells with green fluorescence were sorted by flow cytometry into 96-well plates and cultured for 21 days; (6) Extract the genomic DNA of the hematopoietic stem cells cultured after sorting, detect the integration of SEA Donor DNA and α3.7Donor DNA in the genome by PCR, and confirm the acquisition of gene-repaired hematopoietic stem cells by gene sequencing.
3. The method according to claim 2, It is characterized in that The nucleotide sequences of the gRNA transcription template for -SEA gene repair are SEQ ID NO.1 and SEQ ID NO.2, and the nucleotide sequence of SEA Donor DNA is SEQ ID NO.
5.
4. The method according to claim 2, It is characterized in that The nucleotide sequences of the gRNA transcription template for -α3.7 gene repair are SEQ ID NO.6 and SEQ ID NO.7, and the nucleotide sequence of the SEA Donor DNA is SEQ ID NO.
10.
5. The method according to claim 2, It is characterized in that The E. coli T7 RNA polymerase extracellular transcription method is: (1) Escherichia coli BL21 (DE3) strain was inoculated into LB medium at a ratio of 1% and cultured at 37°C with shaking at 220 rpm / min for 3 h; (2) IPTG at a final concentration of 1 mM induces the lacUV5 promoter to direct the transcription of the T7 RNA polymerase gene to produce T7 RNA polymerase; (3) IPTG induced transcription for 3 h, and the cells were collected and resuspended in 1 / 10 volume of 1 mM Tris-HCl (pH 7.5) of the original LB medium. The cells were disrupted with an ultrasonic disruptor, centrifuged for 5 min, and the supernatant enzyme solution was collected; (4) using a universal nuclease to degrade the DNA and RNA in the enzyme solution, then adding a universal nuclease monoclonal antibody to neutralize the universal nuclease activity, and centrifuging to collect the supernatant, which is the T7 RNA polymerase mixture used for transcription; (5) 50ul of T7 RNA polymerase mixture, 5μL of 10mM ATP, CTP, GTP, and UTP mixture, 1μg of the plasmid to be transcribed, and ultrapure water to make up the reaction system to 100μL. Mix well and transcribe at 37°C for 60min. (6) After transcription, add 5 μL of deoxyribonuclease (DNase) to degrade the DNA in the system; (7) RNA purification to obtain transcribed gRNA or mRNA.
6. The method according to claim 2, It is characterized in that The density of the hematopoietic stem cells during transfection is 1×10 6 cells / mL, and 100μL cells were co-transfected with 2.5μg of SEA Donor DNA and 2.5μg of α3.7 Donor DNA, and 1μg of gRNA1, gRNA2, gRNA3, gRNA4, and Cas9 mRNA.
7. A method for extracellular transcription of Escherichia coli T7 RNA polymerase, It is characterized in that The transcription method is: (1) Escherichia coli BL21 (DE3) strain was inoculated into LB medium at a ratio of 1% and cultured at 37°C with shaking at 220 rpm / min for 3 h; (2) IPTG at a final concentration of 1 mM induces the lacUV5 promoter to direct the transcription of the T7 RNA polymerase gene to produce T7 RNA polymerase; (3) IPTG induced transcription for 3 h, and the cells were collected and resuspended in 1 / 10 volume of 1 mM Tris-HCl (pH 7.5) of the original LB medium. The cells were disrupted with an ultrasonic disruptor, centrifuged for 5 min, and the supernatant enzyme solution was collected; (4) using a universal nuclease to degrade the DNA and RNA in the enzyme solution, then adding a universal nuclease monoclonal antibody to neutralize the universal nuclease activity, and centrifuging to collect the supernatant, which is the T7 RNA polymerase mixture used for transcription; (5) 50ul of T7 RNA polymerase mixture, 5μL of 10mM ATP, CTP, GTP, and UTP mixture, 1μg of template DNA to be transcribed, and ultrapure water to make up the reaction system to 100μL. Mix well and transcribe at 37℃ for 60min. (6) After transcription, add 5 μL of deoxyribonuclease (DNase) to degrade the DNA in the system; (7) RNA purification to obtain transcribed gRNA or mRNA.
